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The experience at the University of Colorado with the
St. Jude Medical cardiac valve was reviewed to deter-
mine the feasibility of placing this prosthesis in children
and the role of anticoagulation. A St. Jude Medical car-
diac valve was placed in 33 patients ranging in age from
2.5 months to 17 years. Seven patients were less than 1
year of age. Nineteen valves were placed in the aortic
position in patients aged 5 months to 17 years (mean 9.5
years). Five patients had valve replacement only, 13had
concomitant aortoventriculoplasty and 1 a Manouguian
procedure. Indications for anulus enlarging procedures
were recurrent subaortic stenosis or inability to place
an adult-sized valve in the native aortic anulus, or both.
There were no early or late deaths.
Fourteen valves were placed in the mitral position.
They were anular positioned in 6 patients aged 6 months
to 16years and supraanular positioned in 8 patients aged
2.5 months to 2 years. There were no deaths with the
anular positioned replacements and seven deaths (two
Controversies concerning valve replacement in children fo-
cus on I) the feasibility of valve replacement in pediatric
patients (1-10), 2) the type of prosthesis to be used (11-18),
and 3) the need for anticoagulation (19-21). The St. Jude
Medical cardiac valve entered clinical trials in 1977 and has
demonstrated excellent results. The all-pyrolytic carbon
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and December 1985 issues of this Journal.
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early and five late) with the supraanular positioned re-
placements. Four of the five late deaths were associated
with marked pre- and postoperative left ventricular dys-
function.
The follow-up time was 784 patient-months in 31 long-
term survivors. Anticoagulation was achieved with war-
farin, usually in combination with sulfinpyrazone, di-
pyridamole or aspirin. There were four episodes of
thromboembolism, three occurring in patients with sub-
optimal anticoagulation, and one in a patient lost to
follow-up.
In conclusion: 1) results of St. Jude Medical cardiac
valve replacement in infants and children are excellent;
2) anticoagulation with warfarin is warranted; and 3)
morbidity and mortality are more often related to the
underlying disease (mitral anular hypoplasia or left ven-
tricular dysfunction, or both) rather than to valve mal-
function.
(1 Am Coil CardioI1987;9:235-9)
prosthesis with its low profile and low thrombogenicity makes
it an attractive choice for valve replacement in children
(22-27). This is a report of the experience at University of
Colorado Health Sciences Center with the St. Jude Medical
cardiac valve in children from October 1980 to September
1984, with follow-up through July 1985.
Methods
Patients. Valves were placed in 33 patients ranging in
age from 2.5 months to 17 years. Seven patients were less
than I year of age. Nineteen patients, aged 5 months to 17
years, had replacement of the aortic valve (Table lA). All
but four patients had prior aortic valve repair. Five patients
had previous aortic valve replacement with a tissue bio-
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Table 1. Summary of 33 Patients Undergoing Valve Replacement With the St. Jude Medical Cardiac Valve
Valve Diameter
Patient Age Diagnosis Previous Surgery (mm) Results
A. Aortic Valve Replacement
I 1/2 yr AS/AI Valvotomy 19 CHF,ARC
2 I yr AS/AI Valvotomy 21 Asymptomatic
3 3 yr AS/AI Valvotomy 21 Asymptomatic
4 3 yr AS/AI Valvotomy 19 Asymptomatic
5 5 yr AI 21 Asymptomatic
6 6 yr AIIVSD VSD repair 21 Asymptomatic
7 7 yr AS/AI Valvotomy 21 Asymptomatic
8 8 yr AS/AI Valvotomy x 2 21 CHB
9 10yr AS/AI Valvotomy 23 Asymptomatic
10 II yr AS/AI Valvotomy 23 Asymptomatic
II 12yr AS/AI 23 Asymptomatic
12 12 yr AI 25 Asymptomatic
13 13 yr SAS/AI Subaortic resection, 21 Asymptomatic
AVR (I-S, 19mm)
14 13 yr AS/MR Valvotomy, 23 Asymptomatic
AVR (I-S, 19mm)
15 15 yr AS/AI Valvotomy, 25 Asymptomatic
AVR (I-S, 14mm)
16 16yr AS/AI AVR (I-S, 19 mm) 25 Asymptomatic
17 16 yr AS/AI AVR (C-E, 23 mm) 23 Asymptomatic
18 17yr AI 21 Asymptomatic
19 17 yr AS Valvotomy 25 Asymptomatic
B. Mitral Valve Replacement, Anular Position
20 112 yr ASD I, MR ASD I repair 4 days 19 CHB
21 3 yr DOMV, Coarc Subclavian flap at 2 yr 21 Asymptomatic
22 9 yr Congenital MR 27 CHB
23 14 yr ASD I, MR ASD I repair at 7 yr 29 Asymptomatic
24 15 yr ASD I, MR ASD I repair at 9 yr 27 Asymptomatic,
paravalvular leak
25 16 yr Rheumatic MR 31 Asymptomatic;
atrial fibrillation
C. Mitral Valve Replacement, Supraanular Position
26 2.5 yr Congenital 19 Asymptomatic
MRiMS
27 5 mo MS/MRISAS 19 Died, 10 mo
28 5 mo ASD I1MS/MR ASD I repair 19 Died, 2 mo
29 6 mo Congenital MS 19 Died, 8 mo
30 7 mo AVC AVC 2 wk prior 19 SAS 31 mo; died
at reoperation
31 I yr MS/Coarc/ ALCPA Subclavian flap I mo 19 Died in OR
32 2 yr Shone's MS/SAS/Coarc Subclavian flap 5 mo, 19 Died, 8 mo
subaortic resection,
MVR (I-S 15) 9 mo
33 2 yr AVS/MS/CoarcIVSD Subclavian flap (8 days) 19 Died, I day
AI aortic insufficiency; ALCPA = anomalous left coronary artery from the pulmonary artery; ARC = AIDS-related complex; AS = aortic
stenosis; ASD I = ostium primum atrial septal defect; AVC = atrioventricular canal; AVR = aortic valve replacement; AVS = aortic valve stenosis;
C-E = Carpentier-Edwards prosthesis; CHB = complete heart block; CHF = congestive heart failure; Coarc = coarctation; DOMV = double orifice
mitral valve; I-S = Ionescu-Shiley prosthesis; MR = mitral regurgitation; MS = mitral stenosis; MVR = mitral valve replacement; OR = operating
room; SAS = subaortic stenosis; VSD = ventricular septal defect.
prosthetic valve 2 to 6 years before the St. Jude Medical
cardiac valve replacement.
Six patients, aged 6 months to 17 years, had mitral valve
replacement in the anular position (Table lB), Four of the
patients had a previous operation 4 days to 7 years before
the mitral valve replacement. One patient had a previous
mitral valve replacement with a porcine bioprosthesis 4 years
before the St. Jude Medical cardiac valve replacement. Eight
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Figure 1. St. Jude Medical cardiac valve replacement in 33chil-
dren.
patients, aged 2,5 months to 2 years, had mitral valve re-
placement in the supraanular position (Table IC), Five pa-
tients had a prior operation and three had a concomitant
procedure with the mitral valve replacement (Patient 27 had
a subaortic resection; Patient 31 had a right subclavianartery
to left coronary artery anastomosis and Patient 33 had an
aortic valvotomy and ventricular septal defect repair),
Procedures and indications. Of the 19 patients with
aortic valve replacement, 5 underwent valve replacement
only (Patients 7, 11, 12, 16 and 17), 1 (Patient 8) had a
Manouguian procedure (aortic anular enlargement with a
posterior patch) and 13 had an aortoventriculoplasty. The
indications for aortoventriculoplasty were I) aortic stenosis
or aortic insufficiency, or both, requiring valve replacement
and inability of the anulus to accept a 19 mm valve; 2)
replacement of a small valve prosthesis; or 3) recurrent,
tunnel subaortic stenosis.
Mitral valve replacement in 14 patients was performed
when there was failure of medical management to control
failure to thrive, congestive heart failure or respiratory dis-
tress. Our indicationfor supraanular positioningof the valve
was an anulus too small to accept a 19 mm prosthesis.
Anticoagulation with warfarin was initiated after the valve
replacement when oral intake was tolerated. Warfarin alone
or in combination with aspirin, dipyridamole or sulfinpyr-
azone was used at the discretion of the attending physicians.
Results
Aortic Valve Replacement
In the 19 cases there were no deaths (Fig. I), Follow-
up ranged from 9 to 48 months (mean 27.3) for a total of
519 patient-months. All patients except one were asymp-
tomatic with normal exercise tolerance. The one patient with
mild congestive heart failure (Patient I) developed an ac-
quired immune deficiency syndrome (AlDS)-related com-
plex. One patient (Patient 8) developed complete heart block
after undergoing the Manouguian procedure and required
permanent pacemaker implantation. Complete right bundle
branch block occurred postoperatively in four patients (Pa-
tients 2, 3, 6 and 10).
Anticoagulant therapy. All 19 patients received anti-
coagulant therapy with warfarin, 4 with warfarin alone; in
12 it was combined with sulfinpyrazone, in 2 with dipyr-
idamole and in I with aspirin. There have been no hem-
orrhagiccomplications. There has been one thromboembolic
episode; a 12 year old child (Patient II) who received war-
farin and sulfinpyrazone developed recurrent transient uni-
lateral hemianopsia when the prothrombin time fell to less
than 15 seconds (Table 2).
Mitral Valve Replacement
Anular position. In these six cases there were no deaths.
Follow-up times ranged from 10 to 38 months (mean 26,6)
for a total of 160 patient-months, All patients are asymp-
tomatic and have normal exercise tolerance. Two patients
developed complete heart block and required permanent
Table 2. Thromboembolism in 33 Pediatric St. Jude Medical Cardiac Valve Replacements
Age at Age at
Patient Repair Thromboembol ism Diagnosis Procedure Complication Anticoagulant
II 12 yr 13 yr Ao-LVtunnel, AVR Hemianopsia W. S,
Al (PT < 15 seconds)
27 5 mo 15 mo ASD I, MS/MR SA-MVR Mitral valve S
thrombosis,
left atrial EFE
30 7 mo 3'12 yr AVC SA-MVR Perivalvular W
pannus (noncompliant)
32 2 yr 3 yr Shone's MS, SA-MVR Mitral valve W,S
previous MVR thrombosis (noncompliant)
Ao = aortic; EFE = endocardial fibroelastosis; LV = left ventricle: PT = prothrombin time; S = sulfinpyrazone; SA = supraanular; W = warfarin;
other abbreviations as in Table I.
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pacing and one patient has atrial fibrillation. One other pa-
tient has a mild paravalvular leak.
All patients underwent anticoagulation with warfarin, two
with additional sulfinpyrazone and one with dipyridamole.
There have been no thromboembolic phenomena or hem-
orrhagic complications.
Supraanular position. In these eight cases there is only
one survivor (Patient 26), and he is asymptomatic at 42
months after repair. Cardiac catheterization 19 months after
repair showed normal ventricular function and a 3 mm Hg
transmitral pressure gradient with trivial mitral regurgita-
tion. There were two early deaths and five late deaths (2 to
31 months postoperatively). Four of the five patients who
died had both pre- and postoperative left ventricular dys-
function. Three underwent postoperative catheterization
showing normal function of the valve prosthesis.
There were two definite thromboembolic episodes in this
group (Table 2). A 3 year old patient (Patient 30) who
complied poorly with warfarin and suifinpyrazone therapy
developed paravalvular fibrin deposition and severe valvular
regurgitation. A I year old patient (Patient 27), in whom
anticoagulation with warfarin was difficult to regulate and
who was eventually treated with only sulfinpyrazone, died
suddenly. Postmortem examination revealed a thrombosed
mitral prosthesis. The other patients received warfarin, two
with and two without suifinpyrazone. A third 3 year old
patient (Patient 32) with poor follow-up was believed to be
receiving warfarin and suifinpyrazone therapy. Two weeks
before death, she developed increasing signs of prosthetic
valve obstruction. Her anticoagulant status is unknown and
no autopsy was performed.
Discussion
Morbidity and mortality. Our experience with the St.
Jude Medical cardiac valve is encouraging. Death occurred
only in patients undergoing supraanular mitral valve re-
placement. Early and late complications after aortic valve
replacement were minimal. Eighteen of the 19 patients are
asymptomatic. The one patient with AIDS-related complex
and congestive heart failure had a normally functioning valve
at postoperative catheterization. One patient developed
complete heart block after the Manouguian procedure and
three had a residual ventricular septal defect after aorto-
ventriculoplasty that required surgical repair in two.
Similarly, there were no deaths after isolated mitral valve
replacement, and all patients are asymptomatic. Two pa-
tients developed complete heart block at the time of surgery.
A third child has a mild paravalvular leak. Mitral valve
replacement in the supraanular position was disappointing,
with only one of the eight patients surviving. The majority
of these patients had coexistence of left ventricular hypo-
plasia and dysfunction.
Anticoagulation. Anticoagulation with warfarin seems
essential in all age groups. During 784 patient-months after
valve replacement there were three definite thromboembolic
episodes and a fourth probable mitral valve thrombosis (Ta-
ble 2). Thesepatients had sinus rhythm and had no clinical
or intraoperative evidence of prior thrombosis. All the ep-
isodes were in patients with suboptimal warfarin therapy;
one occurred in a 15 month old child receiving sulfinpyr-
azone alone.
An argument against anticoagulation has been the risk
of hemorrhage. We observed no hemorrhagic complica-
tions. Prothrombin times are closely followed and regulated
to 18 to 21 seconds by one of us (C.K.M.) every 2 to 4
weeks. Approximately 6 to 8 hours per week are spent
regulating our patients' anticoagulation. The tests are per-
formed in an outpatient laboratory by a finger prick, manual
tilt-tube technique. For patients not living in our immediate
area, our pediatric hematology coagulation section has been
able to help local facilities establish the finger prick tech-
nique. Warfarin is usually taken with dinner or at bedtime.
Prothrombin times are measured at various times of the day
after a 4 to 5 day stabilization after dosage changes. We
encourage our patients to participate in routine acitivity;
however, we counsel them against participating in jumping
activities or contact sports.
We do not have enough information to comment on the
use of antiplatelet agents in combination with warfarin;
however, sulfinpyrazone alone seems inadequate. Even though
there have been no hemorrhagic complications, we no longer
use aspirin in combination with warfarin.
Thromboembolism rates in these patients are similar to
those reported by Nicoloff et al. (24) and Lillehei (25), yet
Pass et al. (20) observed no complications in patients not
receiving anticoagulant agents. Our one patient who was
supposedly taking warfarin and had a probable thrombosis
and the report of McNicholas et al. (21) raise the possibility
that anticoagulation may not be effective or necessary in
controlling thrombosis. Three of our patients who had a
supraanular mitral valve replacement and a thromboembolic
complication had postoperative chronic congestive heart
failure. Possibly the ventricular dysfunction and low cardiac
output were contributing factors to the thrombosis. Ob-
viously, a firm recommendation regarding anticoagulation
would be inappropriate at this time and further follow-up
of these patients will help elucidate this issue.
Conclusions. Review of our experience with these young
patients demonstrates that the St. Jude Medical cardiac valve
is a versatile, well functioning valve suitable for placement
in children. We were able to place the valve safely and
effectively in small infants and older adolescents. All the
deaths occurred in children who had supraanular mitral valve
replacement, whereas other children of the same age and
size survived aortic and mitral anular valve replacement.
We believe that these deaths were related to the underlying
JACC Vol. 9, No.1
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disease rather than to prosthetic valve dysfunction, We have
abandoned supraanular mitral valve replacement in consid-
eration of other surgical options (28,29).
We thank Debra S. Osborne for editorial and secretarial expertise.
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